Protein Summary
Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. In the kidney, the binding of TXA2 to glomerular TP receptors causes intense vasoconstriction. Activates phospholipase C. Isoform 1 activates adenylyl cyclase. Isoform 2 inhibits adenylyl cyclase. This gene encodes a member of the G protein-coupled receptor family. The protein interacts with thromboxane A2 to induce platelet aggregation and regulate hemostasis. A mutation in this gene results in a bleeding disorder. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2009]
- ENST00000375190
- ENSP00000364336
- ENSG00000006638
- ENST00000411851
- ENSP00000393333
- TXA2-R
- BDPLT13
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
ligand (chemical) | 0.96 | ||
histone modification site profile | 0.81 | ||
kinase | 0.72 | ||
tissue sample | 0.69 | ||
biological term | 0.67 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 160.99 (req: < 5)
Gene RIFs: 105 (req: <= 3)
Antibodies: 170 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 160.99 (req: >= 5)
Gene RIFs: 105 (req: > 3)
Antibodies: 170 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 16
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 435
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 4